https://www.dailymail.co.uk/health/article-10875147/Pfizers-vaccine-raked-37-billion-2021-nearly-doubling-revenue-drug.html
Cashing out on Covid! Pfizer's vaccine raked in $37 billion in 2021 - nearly doubling the revenue of every other available drug across ALL markets: US Covid cases approach 100k per day and daily deaths jump above 600
Pfizer raked in $36.8 billion in revenue from its COVID-19 vaccine last year, making it the highest grossing drug in the world last year by a large margin
The jab made nearly double every other drug on the market, with the arthritis drug that proved to be the second leading seller earning $20 billion in 2021
The rollout of the COVID-19 shots has been a boon for Pfizer, making the big pharma brand into a household name and causing its stock price to rocket
US Covid cases are approaching 100,000 per day once again though deaths are still lingering well below 1,000 per day
Big pharma company Pfizer is one of the biggest winners of the COVID-19 pandemic, with a recent report finding that its vaccine was the best selling pharmaceutical drug in the world in 2021 - nearly doubling the revenue figures of all products across the entire market.
A report published Tuesday by Fierce Pharma finds that the Pfizer vaccine, a joint project with the German company BioNTech that is officially branded under the name Comirnaty, made $36.8 billion worth of sales last year, topping the entire global drug market by a large margin.
Humira, an arthritis drug manufactured by AbbVie, comes in at a far second, bringing in $20.7 billion in sales last year. Moderna's vaccine, branded under the title Spikevax, was the third largest pharmaceutical product, earning $17.7 billion in sales - half of its top competitor.
Covid vaccine manufacturers have been under criticism in recent months for prioritization of profits over protection, raking in billions of dollars on selling the drugs to large purchasers like the U.S. and western European nations while leaving others in the developing world behind.
Regulators in the U.S. and elsewhere have been under fire for repeated approval for booster shots - which create more revenue for Pfizer and Moderna - despite limited evidence that more shots are needed to slow the virus's path.
Pfizer projects over $30 billion in revenue from the shots this year, nearly reaching last year's leading total. The company's golden goose may soon stop laying eggs, though.
It is also the manufacturer of Paxlovid, a White House-touted Covid antiviral pill that is believed to be able to reduce hospitalizations and deaths caused by the virus 90 percent.
Interest in the vaccines, and the Covid pandemic overall, has waned among the public. A recent Gallup poll finds that a third of Americans are no longer worried about the pandemic, one of the lowest figures recorded yet.
Case figures are also increasing around the country without translating in hospitalizations and deaths as the same rates they were in previous periods of the pandemic.
According to most recent figures, the nation is averaging 99,748 Covid cases every day, an eight percent drop over the past week. Deaths have not occurred at the same levels, though, with America recording 611 per day.
The nation's booster rollout famously fell flat, with demand for the additional shots being much lower than many officials expected. Now, the White House is having trouble acquiring funding for future pandemic initiatives, which could lead to the country no longer being able to acquire the jabs.